Expert Insights: New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum
Release Date: June 27, 2019
Watch the experts in this stimulating and informative conversation about current practices in and how to care for your patients with prostate cancer. Drs. Neal Shore and Charles Ryan highlight data from the live symposium that will provide guidance to healthcare professionals who are involved in the treatment of prostate cancer through expert interpretation of emerging data and advice regarding the optimization of care of patients with nonmetastatic and metastatic disease.
The target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.
After completing this activity, participants should be better able to:
- Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
- Evaluate currently available treatment options for patients with CRPC
- Identify prostate cancer patients who may benefit from biomarker-directed therapy
- Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Materials will be available online through June 28, 2020.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Conference Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.
All disclosed conflicts of interest have been resolved by independent content review.
Neal Shore - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.
Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme
This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.